On the other hand, these cases argue that there is a need for large scale randomized clinical trials of SGLT2 inhibitors in type 1 diabetes where the benefits and safety issues can be adequately addressed. This evidence concerns the gene SLC5A2 and type 1 diabetes mellitus.